Aadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer

Benzinga2021-11-23

The FDA has approved Aadi Bioscience Inc's Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for perivascular epithelioid cell tumor (PEComa). The approval marks ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

winstonleong
2021-11-23
winstonleong
👌
JS64
2021-11-23
JS64
Ok
- Hodl:
  [Grin]
VickJW
2021-11-23
VickJW
Like and comment please
- MichelleOng:
  Like done
- JS64:
  Done
- ClickLike:
  buy buy buy

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1197163617?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-23 20:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197163617","market":"us","top_or_hot":-1,"title":"Aadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer","media":"Benzinga","content":"<div>\n<p>The FDA has approved Aadi Bioscience Inc's Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for perivascular epithelioid cell tumor (PEComa).\n\n\nThe approval marks ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24244830/aadi-bioscience-shares-rally-on-fda-approval-for-its-first-product-for-rare-form-cancer\">网页链接</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-23 20:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24244830/aadi-bioscience-shares-rally-on-fda-approval-for-its-first-product-for-rare-form-cancer><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has approved Aadi Bioscience Inc's Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for perivascular epithelioid cell tumor (PEComa).\n\n\nThe approval marks ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24244830/aadi-bioscience-shares-rally-on-fda-approval-for-its-first-product-for-rare-form-cancer\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AADI","symbol_name":"Aadi Biosciences, Inc.","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/21/11/24244830/aadi-bioscience-shares-rally-on-fda-approval-for-its-first-product-for-rare-form-cancer","article_id":"1197163617","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197163617","pubTimestamp":1637671759,"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"The FDA has approved Aadi Bioscience Inc's Fyarro (sirolimus protein-bound particles for injectable ","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AADI":"Aadi Biosciences, Inc."},"translate_title":"美国食品和药物管理局批准其首个罕见癌症产品后，Aadi生物科学股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AADI":0.9},"content_text":"The FDA has approved Aadi Bioscience Inc's Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for perivascular epithelioid cell tumor (PEComa).\n\n\nThe approval marks the first and only therapy for adult patients for locally advanced unresectable or metastatic malignant PEComa.\nPEComa is a family of rare tumors that form in the soft tissues of the stomach, intestines, lungs, female reproductive organs, and genitourinary organs.\nIn Phase 2 registrational AMPECT trial, the overall response rate was 39% (12/31), with two patients achieving a Complete Response after prolonged follow-up.\nThe median duration of response has not been reached, with a median follow-up of 36 months.\nAmong responders, 92% had a response lasting greater than or equal to 6 months; 67% had a response lasting up to 12 months, and 58% had a response lasting up to 2 years.\nPrice Action: AADI shares are up 42.6% at $36.39 during the premarket session on the last check Tuesday.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":875400383,"gmtCreate":1637676325940,"gmtModify":1637676326014,"author":{"id":"4099106732701750","authorId":"4099106732701750","name":"winstonleong","avatar":"https://static.tigerbbs.com/4177257e7e08ef417ddd19079ae4139b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4099106732701750","authorIdStr":"4099106732701750"},"htmlText":"👌&nbsp;","listText":"👌&nbsp;","text":"👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875400383","repostId":1197163617,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875555642,"gmtCreate":1637673387920,"gmtModify":1637673388022,"author":{"id":"3582972798563668","authorId":"3582972798563668","name":"JS64","avatar":"https://static.tigerbbs.com/ad519f92a203874c41d7d11080b13d18","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582972798563668","authorIdStr":"3582972798563668"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875555642","repostId":1197163617,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6694305,"gmtCreate":1637676172554,"gmtModify":1637676172584,"authorId":3579666066637422,"author":{"id":3579666066637422,"idStr":"3579666066637422","authorId":3579666066637422,"name":"Hodl","avatar":"https://static.tigerbbs.com/d591a82f579d3114da9795812a4217a0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875555642,"type":1,"supId":0,"prevId":0,"content":"[Grin]","text":"[Grin]","html":"[Grin]"}],"langContent":"CN"},{"id":875524880,"gmtCreate":1637672252853,"gmtModify":1637672252978,"author":{"id":"3578439260866475","authorId":"3578439260866475","name":"VickJW","avatar":"https://static.tigerbbs.com/dc8189137ac06a254539a020b5b368b2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3578439260866475","authorIdStr":"3578439260866475"},"htmlText":"Like and comment please","listText":"Like and comment please","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/875524880","repostId":1197163617,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6708564,"gmtCreate":1637763456648,"gmtModify":1637763456681,"authorId":4093000606743040,"author":{"id":4093000606743040,"idStr":"4093000606743040","authorId":4093000606743040,"name":"MichelleOng","avatar":"https://static.tigerbbs.com/be8a2c49f4c3e66700e24774bbbaa8e5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875524880,"type":1,"supId":0,"prevId":0,"content":"Like done","text":"Like done","html":"Like done"},{"id":6693799,"gmtCreate":1637673395356,"gmtModify":1637673395388,"authorId":3582972798563668,"author":{"id":3582972798563668,"idStr":"3582972798563668","authorId":3582972798563668,"name":"JS64","avatar":"https://static.tigerbbs.com/ad519f92a203874c41d7d11080b13d18","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875524880,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":6693686,"gmtCreate":1637672731176,"gmtModify":1637672731283,"authorId":3559187781517417,"author":{"id":3559187781517417,"idStr":"3559187781517417","authorId":3559187781517417,"name":"ClickLike","avatar":"https://static.tigerbbs.com/31a83d87dc5a6faa4338cc140451880b","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875524880,"type":1,"supId":0,"prevId":0,"content":"buy buy buy","text":"buy buy buy","html":"buy buy buy"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":32,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197163617"}